Month: December 2015

Ameriprise Financial, Inc. AMP continues to reward its shareholders through dividend hikes or additional share repurchases. The company recently announced a new share buyback plan with authorization to repurchase $2.5 billion of shares through Dec 31, 2017. […]

Premium technical services company Jacobs Engineering Group Inc. JEC recently secured its position among the top-tier North American rail service providers by acquiring J.L. Patterson & Associates (‘‘JLP’’) […]

PPG Industries Inc. ’s PPG protective and marine coatings business has introduced the Phenguard Pro tank coating system, which offers unparalleled benefits to shipyards and ship owners. PPG Industries built the system as a premium tank coating solution for use on IMO II and III chemical/product tankers, normally in the 30,000–60,000 pennyweight range. […]

Foreign military sales or FMS in short hand dominated last week’s proceedings in the aerospace and defense space in spite of volatile trading sessions. Lockheed Martin LMT , along with its new member Sikorsky, was in the limelight grabbing major deals. […]

A digital revolution – Financial Technology – commonly known as “FinTech,” is increasingly becoming popular in conducting financial transactions. Apart from making payment processes simple, this growing sector reduces fraud, and save time and money. […]

The Royal Bank of Scotland Group plc RBS is set to record a gain of £245 million in fourth-quarter 2015, as the UK-based banking giant offloads a portfolio of Irish real estate loans. According to the company’s latest release, two subsidiaries of RBS – Ulster Bank Ireland Ltd. (UBIL) and Ulster Bank Ltd […]

On Dec 7, 2015, we issued an updated research report on Ohio-based Steris Plc STE , that develops infection prevention, decontamination, microbial reduction, and surgical and gastrointestinal support products and services. STERIS ended the second quarter of fiscal 2016 on a mixed note. While the bottom line comfortably exceeded the Zacks Consensus Estimate, the top line failed to meet the same […]

Dr Pepper Snapple Group, Inc. DPS launched the new Schweppes Dark Ginger Ale drink to spread holiday cheer. Schweppes Dark Ginger Ale blends in a bolder, darker and richer flavor with its traditional, refreshing ginger ale taste. […]

Along the lines of strategic initiatives to realign its operations, The Manitowoc Company, Inc. MTW declared the sale of its Kysor Panel Systems business to an affiliate of D Cubed Group LLC for approximately $85 million. The transaction is subject to certain adjustments. […]

Ashland Inc. ’s ASH Valvoline Instant Oil Change business – the nation’s second-biggest quick-lube chain – has opened four new company-owned service centers in the Dayton, OH area. These new service centers are located at 1239 Bellefontaine St […]

Celgene Corporation CELG and AstraZeneca AZN announced the initiation of the FUSION development program on investigational human monoclonal antibody directed against programmed cell death ligand 1 (PD-L1), durvalumab (MEDI4736), across blood cancers like non-Hodgkin’s lymphoma (NHL), myelodysplastic syndromes (MDS) and multiple myeloma. The FUSION program comprises four studies – MM-001 (a phase Ib study to determine the recommended dose and regimen of durvalumab as a monotherapy or in combination with pomalidomide, with or without low-dose dexamethasone, in patients with relapsed/refractory multiple myeloma); CC-486-MDS-006 (a phase II study to evaluate the efficacy and safety of CC-486 alone or in combination with durvalumab in patients with MDS, who fail to achieve an objective response to treatment with azacitidine for injection or decitabine); MEDI4736 -NHL-001 (a phase I/II study to assess the safety and tolerability of durvalumab as a monotherapy as well as combination therapy in patients with lymphoma or chronic lymphocytic leukemia); and MEDI4736-MDS-001 (a phase II study to evaluating the efficacy and safety of azacitidine subcutaneous in combination with durvalumab in previously untreated patients with higher-risk myelodysplastic syndromes or in elderly acute myeloid leukemia subjects, who are not eligible for hematopoietic stem cell transplantation). We remind investors that Celgene and AstraZeneca entered the immuno-oncology deal earlier this year […]

Veeva Systems Inc. VEEV is forging ahead with the rollout plans of its advanced business solutions, which will help it to gain market traction. The company introduced two new solutions at the European Commercial Summit, which took place between Dec 2 and Dec 4, 2015. […]

Fluor Corporation FLR recently inked an agreement with the London-based private equity firm Arle Capital Partners to buy Dutch engineering and construction company Stork Holding B.V. Subject to fulfillment of necessary regulatory approvals, the deal will likely close in the first half of 2016. Valued at $755 million, the buyout is expected to supplement Fluor’s earnings per share in 2016 […]

E.coli woes continue for Chipotle Mexican Grill, Inc . CMG . Reportedly, 30 students from Boston College fell ill after eating at one of its restaurants. […]

Roche RHHBY announced positive data from a phase II study, M13-982, on its oncology candidate, venetoclax. Roche is developing venetoclax with AbbVie ABBV for the treatment of patients suffering from previously treated chronic lymphocytic leukemia (CLL) with a 17p deletion. Results of the study showed that treatment with venetoclax resulted in a clinically meaningful reduction in the number of cancer cells. […]

Who says someone’s loss is someone’s gain? Here’s a merger which is a win-win for all the parties involved. […]